In chronic myeloid leukemia (CML), the tumor suppressor TP53 (p53) and the cancer driver MYC mediate the CML network triggered by the fusion protein BCR-ABL, which displays constitutive tyrosine kinase activity. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.